All In Biotech

NDA 020592 · Cheplapharm

Zyprexa

Olanzapine · Oral · Atypical Antipsychotic

Novel

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Sep 30, 1996

Approved uses

9

Original approval plus efficacy supplements

Registered trials

496

150 Phase 3, 32 recruiting

FAERS reports

108,111

93,316 serious, 13,364 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with...

What it is approved for

From the label in effect Oct 6, 2026.

ZYPREXA ® (olanzapine) is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As ZYPREXA IntraMuscular for the: Treatment of acute agitation associated with schizophrenia and bipolar I mania....

Mechanism: The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • ZYPREXA · OLANZAPINE 20MG · TABLET, ORAL · Prescription · TE AB
  • ZYPREXA · OLANZAPINE 10MG · TABLET, ORAL · Prescription · TE AB
  • ZYPREXA · OLANZAPINE 5MG · TABLET, ORAL · Prescription · TE AB
  • ZYPREXA · OLANZAPINE 15MG · TABLET, ORAL · Prescription · TE AB
  • ZYPREXA · OLANZAPINE 7.5MG · TABLET, ORAL · Prescription · TE AB
  • ZYPREXA · OLANZAPINE 2.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Olanzapine" as an intervention, any sponsor and status, largest first.

All 496 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,525
  • weight increased6,834
  • off label use6,066
  • diabetes mellitus5,394
  • toxicity to various agents4,383
  • drug interaction4,289
  • nausea4,114
  • somnolence4,007
  • fatigue3,663
  • anxiety3,460
  • overdose3,449
  • vomiting3,326

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,191
20053,175
20063,603
20073,532
20081,855
20093,604
20103,238
20113,251
20122,970
20132,560
20142,945
20157,854
20163,892
20174,788
20186,068
20196,665
20206,148
20216,265
20227,084
20236,875
20247,033
20257,207
20265,307

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zyprexa* (Olanzapine)

2024 spending

$12.4M

Beneficiaries

1,208

8,883 claims

Per beneficiary

$10,232

$29.03 per unit

View as table
YearSpending
2020$18,507,490
2021$17,331,354
2022$15,998,193
2023$15,496,874
2024$12,359,907

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,214 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.